Title |
An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER)
|
---|---|
Published in |
Cardiovascular Drugs and Therapy, March 2018
|
DOI | 10.1007/s10557-018-6782-1 |
Pubmed ID | |
Authors |
Fumiki Yoshihara, Miki Imazu, Toshimitsu Hamasaki, Toshihisa Anzai, Satoshi Yasuda, Shin Ito, Haruko Yamamoto, Kazuhiko Hashimura, Yoshio Yasumura, Kiyoshi Mori, Masataka Watanabe, Masanori Asakura, Masafumi Kitakaze, on behalf of the DAPPER investigators and study coordinators |
Abstract |
Sodium-dependent glucose transporter-2 (SGLT-2) inhibitors, which are anti-diabetic drugs, reportedly decrease the incidence of cardiovascular events in high-risk patients with cardiovascular diseases, and thus chronic heart failure (CHF). SGLT-2 inhibitors also decrease albuminuria in patients with type 2 diabetes mellitus (T2D). Since albuminuria is a biomarker of not only chronic kidney disease but also cardiovascular events, we hypothesized that, among T2D patients with CHF, SGLT-2 inhibitors will decrease the extent of albuminuria and also improve CHF concomitantly. DAPPER (UMIN000025102) is a multicenter, randomized, open-labeled, parallel-group, standard treatment-controlled study, which is designed to evaluate whether dapagliflozin, one of the SGLT-2 inhibitors, decreases albuminuria in T2D patients with CHF and exerts cardioprotective effects on the failing heart. The patients are randomized to either of the dapagliflozin (5 or 10 mg, once daily orally) or control group (administration of anti-diabetic drugs administered other than SGLT 2 inhibitors). The estimated number of patients that need to be enrolled is 446 in total (223 in each group). The primary objective is the changes in the urinary albumin-to-creatinine ratio from the baseline after 2-year treatment. The key secondary objectives are (1) the safety of dapagliflozin and (2) the cardiovascular and renal efficacies of dapagliflozin. DAPPER study investigates whether dapagliflozin decreases albuminuria and exerts beneficial effects on the failing heart in T2D patients. (UMIN000025102). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 18 | 42% |
Paraguay | 2 | 5% |
Argentina | 2 | 5% |
Mexico | 2 | 5% |
Chile | 1 | 2% |
Venezuela, Bolivarian Republic of | 1 | 2% |
Thailand | 1 | 2% |
Unknown | 16 | 37% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 35 | 81% |
Practitioners (doctors, other healthcare professionals) | 5 | 12% |
Science communicators (journalists, bloggers, editors) | 2 | 5% |
Scientists | 1 | 2% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 95 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 12% |
Student > Bachelor | 11 | 12% |
Student > Master | 9 | 9% |
Student > Ph. D. Student | 7 | 7% |
Student > Doctoral Student | 5 | 5% |
Other | 14 | 15% |
Unknown | 38 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 40 | 42% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
Nursing and Health Professions | 4 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 1% |
Chemical Engineering | 1 | 1% |
Other | 4 | 4% |
Unknown | 41 | 43% |